Pharmacokinetics of Piperacillin/Tazobactam in Patients Treated by Continuous Renal Replacement Therapy
NCT ID: NCT00703144
Last Updated: 2013-01-24
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
10 participants
INTERVENTIONAL
2008-06-30
2012-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Pharmacokinetics of Piperacillin and Tazobactam in Critically Ill Patients
NCT03738683
Evaluation of the Dialytic Clearance of the Combination of Peracillin and Tazobactam
NCT07167524
Assessment of the Optimal Dosing of Piperacillin-tazobactam in Intensive Care Unit Patients: Extended Versus Continuous Infusion
NCT01198925
PCR Technic Evaluation in the Microbial Diagnostic of Septicemia in Hemodialysis Patients With Catheter.
NCT04026035
Piperacillin-Tazobactam Continuous Versus Intermittent Infusion for Pseudomonas Aeruginosa
NCT01577368
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Continuous replacement therapy has a continuous effect on drug elimination which could compromise effective antibiotic treatment.
Patients will receive a standard course of pip/tazo 4g intravenously 8 hourly administrated immediately when CVVHDF will be started.
Blood samples will be collected at 30mn, 2h, 4h, 6h, 8h, 16h, 24h for the first and the second day.
We will measure plasma piperacillin/tazobactam concentration and compare them to MICs for the whole dosing interval.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Pharmacokinetic
piperacillin/tazobactam
piperacillin 4 g and tazobactam 500 mg during 30 min IV infusion every 8h during 2 consecutive days
Pharmacokinetic
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
piperacillin/tazobactam
piperacillin 4 g and tazobactam 500 mg during 30 min IV infusion every 8h during 2 consecutive days
Pharmacokinetic
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Females of childbearing potential must have a negative pregnancy test at screening.
* Subjects whose life expectancy is estimated over 7 days.
* Anuric patients requiring continuous venovenous hemodiafiltration
* Septic patients,severe sepsis or septic shock
* Written informed consent should be given either by the patient or a member of his family
Exclusion Criteria
* Pathogens whose antibiotic susceptibility is not proved.
* Patients having impaired hepatic function
* Contraindication of anticoagulation by heparin
* Residual renal function
* Participation in a clinical trial
* Interruption of treatment by piper/tazo or hemodiafiltration during the study.
* Patients with psychiatric disorder or serious medical condition which in the opinion of the investigator may lead to complexity in patient management.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University Hospital, Toulouse
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
LAVAYSSIERE Laurence, MD
Role: PRINCIPAL_INVESTIGATOR
University Hospital, Toulouse
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Service de Néphrologie
Toulouse, , France
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
University Hospital Toulouse
Identifier Type: -
Identifier Source: secondary_id
07 300 02
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.